Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Capecitabine
Related studies linked through entity extraction aliases.
Immunotherapy In Locally Advanced Rectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy
- Status
- UNKNOWN
- Phase
- NA
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
- Status
- COMPLETED
- Phase
- PHASE3
RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study)
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE3
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
Study of CPI-100 in Patients With Advanced Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection
- Status
- UNKNOWN
- Phase
- PHASE3
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2